PLA2G5
Phospholipase A2 Group V
Gene Information Card
| Symbol | PLA2G5 |
|---|---|
| Full Name | Phospholipase A2 Group V |
| Gene Type | protein-coding |
| Chromosomal Location | 1p36.12 |
| NCBI Gene ID | 5322 ncbi.nlm.nih.gov/gene/5322 |
| Ensembl ID | ENSG00000117461 |
| UniProt ID | P39877 |
| OMIM ID | 601699 |
| HGNC ID | 9038 |
| Aliases | sPLA2-V, GV-PLA2, PLA2V |
Description
PLA2G5 encodes group V secretory phospholipase A2 (sPLA2-V), an enzyme that catalyzes the hydrolysis of membrane phospholipids to release arachidonic acid and lysophospholipids. This protein plays a key role in eicosanoid biosynthesis, inflammation, and lipid metabolism. It is expressed in various tissues and is implicated in atherosclerosis, asthma, and cancer progression.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Atherosclerosis | sPLA2-V promotes LDL modification and foam cell formation via hydrolysis of phospholipids in arterial walls. | NCBI Gene, OMIM |
| Asthma | Increased sPLA2-V activity in airway epithelial cells contributes to eicosanoid-mediated inflammation and bronchoconstriction. | NCBI Gene, OMIM |
| Colorectal Cancer | Overexpression of PLA2G5 in tumor cells enhances prostaglandin E2 production, promoting cell proliferation and invasion. | COSMIC, NCBI Gene |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Heart | 4.2 | Low |
| Lung | 8.7 | Medium |
| Liver | 1.3 | Not detected |
| Kidney | 3.5 | Low |
| Spleen | 12.1 | Medium |
| Small Intestine | 6.8 | Medium |
| Colon | 5.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| A549 (lung carcinoma) | 15.3 | High expression |
| HCT116 (colorectal carcinoma) | 9.8 | Medium expression |
| THP-1 (monocyte) | 7.2 | Medium expression |
| HEK293 (embryonic kidney) | 2.1 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.245G>A (p.Arg82His) | Missense | <0.01% | Unknown functional impact; reported in ClinVar |
| c.331C>T (p.Arg111Trp) | Missense | <0.01% | Potential loss of catalytic activity |
| c.412_413insA (p.Thr138Asnfs*5) | Frameshift | <0.01% | Predicted loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the protein or disrupt the catalytic site are predicted to cause loss of enzymatic activity.
Gain of Function (GOF)
No gain-of-function mutations have been reported in PLA2G5.
Dominant Negative (DN)
No dominant-negative mutations have been described for PLA2G5.
View complete mutation data：
Gene Ontology (GO)
| • phospholipase A2 activity | • calcium ion binding |
| • lipid catabolic process | • inflammatory response |
| • arachidonic acid secretion |
Pathways
• Arachidonic acid metabolism
• Eicosanoid synthesis
• Inflammatory mediator regulation of TRP channels
Protein Summary
The PLA2G5 protein (group V secretory phospholipase A2) is a 138-amino acid enzyme that hydrolyzes phospholipids at the sn-2 position, releasing arachidonic acid and lysophospholipids. It is secreted by inflammatory cells and acts extracellularly to modulate lipid signaling. The protein contains a conserved Ca2+-binding loop and a catalytic His-Asp dyad. Its expression is upregulated in inflammatory conditions and certain cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PLA2G5 Knockout HEK293 Cell Line | EDJ-KQ1264 | Human | 5322 | Details Get a Quote |
| PLA2G5 Knockout HeLa Cell Line | EDJ-KQ54151 | Human | 5322 | Details Get a Quote |
| PLA2G5 Knockout A-549 Cell Line | EDJ-KQ62644 | Human | 5322 | Details Get a Quote |
| PLA2G5 Knockout HCT 116 Cell Line | EDJ-KQ71112 | Human | 5322 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
